Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2014 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present at the Stifel 2014 Healthcare Conference

PORTLAND, Ore., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address...
November 11, 2014 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Doses First Patient in Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) in Combination With Herceptin(R) (trastuzumab) to Treat High-Risk HER2 3+ or HER2 Gene-Amplified Breast Cancer Patients

Trial expands the eligible patient population and overall NeuVax clinical trial portfolio Recent patent allowance provides intellectual property protection for NeuVax in combination with...
November 07, 2014 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Presents GALE-301 (Folate Binding Protein Immunotherapy) Phase 2a Clinical Trial Data at the Society for Immunotherapy of Cancer (SITC) 29th Annual Meeting

Preliminary data shows a 31% recurrence rate in the vaccine group compared to 50% in the control group at a median follow up of 13 months, a 38% reduction in relative risk of...
November 04, 2014 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present GALE-301 (Folate Binding Protein) Phase 2a Clinical Trial Data at the Society for the Immunotherapy of Cancer (SITC) 29th Annual Meeting on Friday, November 7, 2014

PORTLAND, Ore., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address...
November 03, 2014 16:20 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Reports Third Quarter 2014 Results

Clinical programs advance on multiple fronts, with trial initiation, trial enrollment, data and IP milestones achieved and anticipated Commercial strategy reinforced with product...
October 27, 2014 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Report Third Quarter 2014 Financial Results on Monday, November 3, 2014

PORTLAND, Ore., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address...
October 14, 2014 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Receives Notice of Allowance of Improvement Patent for NeuVax(TM) (nelipepimut-S) in Japan

- Allowed claims will cover the use of NeuVax alone or in combination to prevent recurrence of any breast cancer tumor expressing low-to-intermediate levels of HER2 - Extends...
October 08, 2014 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Announces Notice of Allowance of U.S. Patent Application for NeuVax(TM) (nelipepimut-S) Combination

PORTLAND, Ore., Oct. 8, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address...
September 25, 2014 16:15 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Announces Release of Special Committee Report and Hosting of a Conference Call to Provide a Corporate Update

PORTLAND, Ore., Sept. 25, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE) today announced the release of a report prepared by the former Special Committee of Galena's Board of Directors...
September 09, 2014 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Doses First Patient in GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial

PORTLAND, Ore., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address...